Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018

INTERNATIONAL JOURNAL OF CARDIOLOGY

卷:272

Article

Olschewski, Horst¹  Behr, Juergen^2,3  Bremer, Hinrich⁴  Claussen, Martin^5,6  Douschan, Philipp¹  Halank, Michael⁷  Held, Matthias⁸  Hoeper, Marius M.^9,10  Holt, Stephan¹¹  Klose, Hans¹²  Krueger, Stephan^13,14  Lange, Tobias J.¹⁵  Reichenberger, Frank^2,3  Skowasch, Dirk¹⁶  Ulrich, Silvia¹⁷  Wilkens, Heinrike¹⁸  Seeger, Werner^19,20 

[1] Med Univ Graz, Univ Klin Innere Med, Klin Abt Lungenkrankheiten, Auenbruggerpl 15, A-8036 Graz, Austria

[2] Univ Munich, Med Klin & Poliklin 5, Comprehens Pneumol Ctr, Munich, Germany

[3] DZL, Heidelberg, Germany

[4] Villingen Schwenningen GmbH, Schwarzwald Baar Klinikum, Villingen, Germany

[5] LungenClin Grosshansdorf GmbH, Zentrum Pneumol & Thoraxchirurg, Grosshansdorf, Germany

[6] DZL, Grosshansdorf, Germany

[7] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin 1, Dresden, Germany

[8] Missionsarztliche KlinikWurzburg, Innere Med Abt, Zentrum Pulm Hypertonie & Lungengefasserkrankunge, Wurzburg, Germany

[9] Hannover Med Sch, Klin Pneumol, Hannover, Germany

[10] DZL, Hannover, Germany

[11] Univ Cologne, Pneumol Inst, Krankenhaus Bethanien Solingen, Cologne, Germany

[12] Univ Klinikum Hamburg Eppendorf, Onkol Zentrum, Med Klin & Poliklin 2, Sekt Pneumol, Hamburg, Germany

[13] Florence Nightingale Krankenhaus, Klin Pneumol Kardiol & Internist Intens Med, Dusseldorf, Germany

[14] Univ Klinikum Dusseldorf, Klin Kardiol Pneumol & Angiol, Dusseldorf, Germany

[15] Uniklin Regensburg, Klin & Poliklin Innere Med 2, Regensburg, Germany

[16] Univ Klinikum Bonn, Med Klin & Poliklin 2, Sekt Pneumol, Bonn, Germany

[17] Univ Spital Zurich, Klin Pneumol, Zurich, Switzerland

[18] Univ Klinikum Saarlandes, Innere Med Pneumol Allergol Beatmungs & Umweltmed, Homburg, Germany

[19] Univ Giessen & Marburg Lung Ctr UGMLC, Med Klin & Poliklin 2, Giessen, Germany

[20] DZL, Giessen, Germany

关键词: Pulmonary hypertension;    Lung disease;    COPD;    Pulmonary fibrosis;    Therapy;   

DOI  :  10.1016/j.ijcard.2018.08.043

来源: Elsevier

【 摘 要 】

The 2015 European Guidelines on Pulmonary Hypertension did not only cover pulmonary arterial hypertension (PAH) but also some aspects of pulmonary hypertension (PH) associated with chronic lung disease. The European Guidelines point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, sGC stimulators) have not been sufficiently investigated in other forms of PH. Therefore, the European Guidelines do not recommend the use of these drugs in patientswith chronic lung disease and PH. This recommendation, however, is not always in agreement with medical ethics as physicians sometimes feel inclined to treat other forms of PHwhichmay affect quality of life and survival of these patients in a similar manner. To this end, it is crucial to consider the severity of both PH and the underlying lung disease. In June 2016, a Consensus Conference organized by the PHworking groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Paediatric Cardiology (DGPK) was held in Cologne, Germany, to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were created, one of which was dedicated to the diagnosis and treatment of PH in patients with chronic lung disease. The 2018 updated recommendations of this working group are summarized in the present paper. (c) 2018 Published by Elsevier B.V.

【 授权许可】

Free